Inclusion Criteria:

          -  Male and female ≥ 18 years old

          -  Triple Negative Breast Cancer participants only: Participant must have histologically
             or cytologically confirmed metastatic or locally recurrent estrogen receptor
             (ER)-negative (<1% by immunohistochemistry [IHC]), progesterone receptor (PR)-negative
             (<1% IHC) and human epidermal growth factor receptor 2 (Her2)-negative (either
             fluorescent in situ hybridisation [FISH] negative, 0 or 1+ by IHC, or IHC2+ and FISH
             negative per ASCO/CAP definition) breast cancer. Participant must be
             relapsed/refractory to at least one line of systemic chemotherapy in the metastatic
             setting or intolerant of existing therapy(ies) known to provide clinical benefit for
             their condition. Prior exposure to an immune checkpoint inhibitor is allowed.

          -  Platinum-Resistant High Grade Serous Ovarian Cancer, primary peritoneal cancer and/or
             fallopian-tube cancer participants only: Participant must have histologically or
             cytologically confirmed diagnosis of metastatic or unresectable high grade serous
             ovarian cancer, with platinum-resistance defined as progression during or within 6
             months of a platinum-containing regimen. Prior exposure to platinum-resistant
             recurrence therapy is allowed.

          -  Serous Endometrial Cancer participants only (Dose Exploration only): Participant must
             have histologically or cytologically confirmed diagnosis of metastatic or recurrent
             serous endometrial cancer, and be relapsed/refractory to at least one line of systemic
             therapy in the metastatic/recurrent setting or intolerant of existing therapy(ies)
             known to provide clinical benefit for their condition.

          -  Participants with advanced or metastatic solid tumor with TP53MUT (Dose Exploration
             only, as assessed by local testing) that is unresectable and relapsed/refractory to at
             least one line of systemic chemotherapy or intolerant.

        Exclusion Criteria:

          -  Active brain metastases.

          -  Primary CNS tumor, hematological malignancies or lymphoma.

          -  Uncontrolled pleural effusions(s), pericardial effusion, or ascites.

          -  Gastrointestinal (GI) tract disease causing the inability to take oral medication.